$CLRB
Cellectar Biosciences, Inc.

2023 Q1 Form 10-K Financial Statement

#000141057823000224 Filed on March 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.051M $1.969M $9.594M
YoY Change -8.96% 28.24% 46.59%
% of Gross Profit
Research & Development $6.654M $5.454M $19.22M
YoY Change 71.19% 24.28% 9.29%
% of Gross Profit
Depreciation & Amortization $42.56K $38.16K $148.0K
YoY Change -1.98% -2.9% -1.28%
% of Gross Profit
Operating Expenses $6.654M $7.423M $19.22M
YoY Change 71.19% 25.31% 9.29%
Operating Profit -$8.705M -$28.81M
YoY Change 41.77% 19.4%
Interest Expense $124.0K $147.4K $152.5K
YoY Change 28745.12% -11185.71% 6577.71%
% of Operating Profit
Other Income/Expense, Net $124.0K $152.5K
YoY Change 28745.12% 1610.24%
Pretax Income -$8.581M -$7.275M -$28.66M
YoY Change 39.76% 22.93% 18.82%
Income Tax -$60.00K -$60.00K
% Of Pretax Income
Net Earnings -$8.581M -$7.215M -$28.60M
YoY Change 39.76% 21.92% 18.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.76 -$4.05
Diluted Earnings Per Share -$0.76 -$0.73 -$4.05
COMMON SHARES
Basic Shares Outstanding 9.741M 9.385M 7.056M
Diluted Shares Outstanding 11.26M 7.056M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.68M $19.87M $19.87M
YoY Change -58.6% -44.36% -44.36%
Cash & Equivalents $12.68M $19.87M $19.87M
Short-Term Investments
Other Short-Term Assets $1.164M $663.2K $663.2K
YoY Change 53.04% -23.54% -23.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.85M $20.53M $20.53M
YoY Change -55.9% -43.86% -43.86%
LONG-TERM ASSETS
Property, Plant & Equipment $376.1K $418.6K $979.0K
YoY Change 13.57% 21.52% 78.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.214K $6.214K $81.21K
YoY Change -92.35% 0.0% 0.0%
Total Long-Term Assets $992.0K $1.060M $1.060M
YoY Change 66.55% 68.19% 68.19%
TOTAL ASSETS
Total Short-Term Assets $13.85M $20.53M $20.53M
Total Long-Term Assets $992.0K $1.060M $1.060M
Total Assets $14.84M $21.59M $21.59M
YoY Change -53.62% -41.97% -41.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.905M $2.558M $4.195M
YoY Change 53.04% 80.78% 196.5%
Accrued Expenses $51.11K $50.85K $1.334M
YoY Change -63.39% -62.46% 92.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.956M $5.529M $5.529M
YoY Change 49.54% 38.57% 38.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $548.3K $553.0K $553.0K
YoY Change 322.74% 232.54% 232.54%
Total Long-Term Liabilities $548.3K $553.0K $553.0K
YoY Change 322.74% 232.54% 232.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.956M $5.529M $5.529M
Total Long-Term Liabilities $548.3K $553.0K $553.0K
Total Liabilities $7.504M $6.082M $6.082M
YoY Change 56.95% 46.33% 46.33%
SHAREHOLDERS EQUITY
Retained Earnings -$179.5M
YoY Change 18.95%
Common Stock $97.00 $94.00
YoY Change -84.12% 54.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.334M $15.51M $15.51M
YoY Change
Total Liabilities & Shareholders Equity $14.84M $21.59M $21.59M
YoY Change -53.62% -41.97% -41.97%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$8.581M -$7.215M -$28.60M
YoY Change 39.76% 21.92% 18.57%
Depreciation, Depletion And Amortization $42.56K $38.16K $148.0K
YoY Change -1.98% -2.9% -1.28%
Cash From Operating Activities -$7.184M -$7.412M -$25.22M
YoY Change 42.54% 64.3% 11.76%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $117.9K $226.0K
YoY Change -100.0% -190.84% 59.85%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$117.9K -$226.0K
YoY Change -100.0% -9.16% 59.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.611M
YoY Change 27459.01%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000 9.611M 9.611M
YoY Change 669.59%
NET CHANGE
Cash From Operating Activities -7.184M -7.412M -25.22M
Cash From Investing Activities 0.000 -117.9K -226.0K
Cash From Financing Activities 3.000 9.611M 9.611M
Net Change In Cash -7.184M 2.081M -15.84M
YoY Change 41.69% -144.84% -26.2%
FREE CASH FLOW
Cash From Operating Activities -$7.184M -$7.412M -$25.22M
Capital Expenditures $0.00 $117.9K $226.0K
Free Cash Flow -$7.184M -$7.530M -$25.45M
YoY Change 41.69% 71.86% 12.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001279704
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478443
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3854914
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50847
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
135449
CY2022Q2 clrb Stockholder Equity Note Stock Split Conversion Ratio1
StockholderEquityNoteStockSplitConversionRatio1
0.10
CY2022Q2 clrb Stockholder Equity Note Stock Split Conversion Ratio1
StockholderEquityNoteStockSplitConversionRatio1
0.10
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
333-119366
CY2022 dei Entity Registrant Name
EntityRegistrantName
CELLECTAR BIOSCIENCES, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3321804
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2022 dei City Area Code
CityAreaCode
608
CY2022 dei Local Phone Number
LocalPhoneNumber
441-8120
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
CY2022 dei Trading Symbol
TradingSymbol
CLRB
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
24322264
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9740507
CY2022 dei Auditor Firm
AuditorFirmId
23
CY2022 dei Auditor Name
AuditorName
Baker Tilly US, LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19866358
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35703975
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
663243
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
867485
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20529601
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36571460
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
344491
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
560334
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
204644
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
75000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
75000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6214
CY2022Q4 us-gaap Assets
Assets
21589790
CY2021Q4 us-gaap Assets
Assets
37201809
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.05
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.05
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5529290
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3990363
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
552981
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
166292
CY2022Q4 us-gaap Liabilities
Liabilities
6082271
CY2021Q4 us-gaap Liabilities
Liabilities
4156655
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
111
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
111
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1382023
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9385272
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9385272
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6110125
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6110125
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
94
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
61
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193624445
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
182560859
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179499043
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150897789
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21589790
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37201809
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19219603
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17586469
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9594170
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6544811
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
28813773
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
24131280
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-28813773
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-24131280
CY2021 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
6634
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
152519
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2284
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
152519
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8918
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28661254
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24122362
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601254
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24122362
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.35
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.35
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7055665
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7055665
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5551572
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5551572
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
54794529
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1124190
CY2021 clrb Conversion Of Warrants Value For Common Shares
ConversionOfWarrantsValueForCommonShares
1213924
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34873
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24122362
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
33045154
CY2022 clrb Stock Issued During Period Value Pre Funded Warrants And Warrants Net Of Issuance Costs
StockIssuedDuringPeriodValuePreFundedWarrantsAndWarrantsNetOfIssuanceCosts
9610655
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1452964
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601254
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15507519
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601254
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24122362
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148435
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
149915
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1452964
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1124190
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3386
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2937
CY2022 clrb Non Cash Lease Expense
NonCashLeaseExpense
90432
CY2021 clrb Non Cash Lease Expense
NonCashLeaseExpense
77721
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-204242
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
93053
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1623529
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
411717
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-144035
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-119903
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25222301
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22568838
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225971
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
141361
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-225971
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-141361
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9610655
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34873
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1213924
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9610655
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1248797
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15837617
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21461402
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57165377
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19866358
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
54000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35703975
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
18653826
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179499000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-28601000
CY2022Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10700000
CY2022Q4 clrb Net Proceeds From Issuance Or Sale Of Equity
NetProceedsFromIssuanceOrSaleOfEquity
9600000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span> — The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities. On an on-going basis, management evaluates its estimates including those related to unbilled vendor amounts and share-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from those estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2021 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2022 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2021Q4 clrb Clinical Trial Costs Current
ClinicalTrialCostsCurrent
1881000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
359000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span> — Financial instruments that subject the Company to credit risk consist of cash and cash equivalents on deposit with financial institutions. The Company’s excess cash as of December 31, 2022 and 2021 is on deposit in interest-bearing accounts with well-established financial institutions. At times, such amounts may exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits. As of December 31, 2022, uninsured cash balances totaled approximately $19,400,000.</p>
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
19400000
CY2022 clrb Proceeds From Cancer Treatment
ProceedsFromCancerTreatment
2000000.0
CY2022 clrb Proceeds From Research And Development
ProceedsFromResearchAndDevelopment
697000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1111175
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
889267
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
692534
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
544776
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418641
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
344491
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
150000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
916000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
504000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2558000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1415000
CY2022Q4 clrb Clinical Trial Costs Current
ClinicalTrialCostsCurrent
1637000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
712431
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
537453
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
19.92
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.25
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
13.90
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5478000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3855000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022 clrb Preferred Stock Convertible Beneficial Conversion Feature
PreferredStockConvertibleBeneficialConversionFeature
0
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8590424
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
440250
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
353750
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1452964
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1124190
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
281000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.49
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.40
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
9.80
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
7.33
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
10.20
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
135986
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
38101
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
343996
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
72613
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.20
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
14.40
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1884149
CY2022 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
1279112
CY2022 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
535413
CY2022 clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
69624
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-60000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-60000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-7800350
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-7102248
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2633146
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1071157
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10433496
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8173405
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10433496
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8173405
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35958687
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
32696266
CY2022Q4 clrb Deferred Tax Assets Tax Credit Carry Forwards Domestic Research And Development
DeferredTaxAssetsTaxCreditCarryForwardsDomesticResearchAndDevelopment
11484209
CY2021Q4 clrb Deferred Tax Assets Tax Credit Carry Forwards Domestic Research And Development
DeferredTaxAssetsTaxCreditCarryForwardsDomesticResearchAndDevelopment
9599756
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
6186679
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
5305170
CY2022Q4 clrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Cost
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost
15820893
CY2021Q4 clrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Cost
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCost
12089171
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3186702
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2627881
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
443693
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
231586
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73080863
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
62549830
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
157498
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
59961
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
157498
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
59961
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
72923365
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
62489869
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
72923365
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62489869
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0935
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0351
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0657
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.1051
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3640
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3388
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0031
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0113
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0020
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022 clrb Net Operating Loss Carryforwards Expiration Period
NetOperatingLossCarryforwardsExpirationPeriod
60,661,000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
404570
CY2022Q4 clrb Research And Development And Investment Tax Credits
ResearchAndDevelopmentAndInvestmentTaxCredits
24742
CY2022 clrb Research And Development And Investment Tax Credits Expiration Period
ResearchAndDevelopmentAndInvestmentTaxCreditsExpirationPeriod
2022
CY2022Q4 us-gaap Area Of Land
AreaOfLand
3983
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2022 us-gaap Payments For Rent
PaymentsForRent
11800
CY2022 clrb Increase In Percentage Of Rent
IncreaseInPercentageOfRent
0.02
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.14
CY2018Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
131000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
132000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
147000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
150000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
153000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
207000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
920000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
316000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
604000

Files In Submission

Name View Source Status
clrb-20221231_cal.xml Edgar Link unprocessable
clrb-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clrb-20221231x10k_htm.xml Edgar Link completed
0001410578-23-000224-index-headers.html Edgar Link pending
0001410578-23-000224-index.html Edgar Link pending
0001410578-23-000224.txt Edgar Link pending
0001410578-23-000224-xbrl.zip Edgar Link pending
clrb-20221231.xsd Edgar Link pending
clrb-20221231x10k.htm Edgar Link pending
clrb-20221231xex10d26.htm Edgar Link pending
clrb-20221231xex10d26g001.jpg Edgar Link pending
clrb-20221231xex10d26g002.jpg Edgar Link pending
clrb-20221231xex10d26g003.jpg Edgar Link pending
clrb-20221231xex10d26g004.jpg Edgar Link pending
clrb-20221231xex10d26g005.jpg Edgar Link pending
clrb-20221231xex10d26g006.jpg Edgar Link pending
clrb-20221231xex10d26g007.jpg Edgar Link pending
clrb-20221231xex10d26g008.jpg Edgar Link pending
clrb-20221231xex10d26g009.jpg Edgar Link pending
clrb-20221231xex10d26g010.jpg Edgar Link pending
clrb-20221231xex10d26g011.jpg Edgar Link pending
clrb-20221231xex21d1.htm Edgar Link pending
clrb-20221231xex23d1.htm Edgar Link pending
clrb-20221231xex31d1.htm Edgar Link pending
clrb-20221231xex31d2.htm Edgar Link pending
clrb-20221231xex32d1.htm Edgar Link pending
clrb-20221231xex4d3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
clrb-20221231_def.xml Edgar Link unprocessable
clrb-20221231_lab.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending